FDA advisers backed six peptides in July. None is on the compounding list yet
Photo: HD Wallpapers / StockSnap (CC0) / own upload
More than ten weeks after the vote, the federal list that pharmacies compound from still contains no peptides.
An FDA advisory committee voted on 23β24 July 2026 to recommend adding BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon to the Section 503A bulks list, even though FDA's own briefing documents proposed adding none of them. A dated status review published on 3 October found that none has been added: the final list in 21 CFR 216.23 still names six substances, and none is a peptide. Adding any of them would take a proposed rule, a comment period and a final rule, and a committee vote is not FDA approval.
Why it's hot: The 3 October review is the newest dated status check on a decision still pending.
What people are searching
Photo: Scott Webb / StockSnap (CC0) / own upload
fda peptide ban 2026 update β Same question, broader wording
Photo: kinkate / StockSnap (CC0) / own upload
503a bulks list peptides β The list that would have to change
Photo: sasint / StockSnap (CC0) / own upload
fda import alert 66-80 β September import alert on GLP-1-class bulk ingredients
Photo: Filip Mroz / StockSnap (CC0) / own upload
peptide coa verification β Checking batch documentation
FDA Watch
Research-community awareness only β not legal advice.
Photo: Burst / StockSnap (CC0) / own upload
Six peptides recommended by FDA advisers in July are still not on the final 503A list; no proposed rule found in the Federal Register. PeptidePrescriber status review; eCFR 21 CFR 216.23 Related
Photo: Burst / StockSnap (CC0) / own upload
Import Alert 66-80 lets FDA detain imported GLP-1-class bulk ingredients unless the maker is on its Green List. U.S. FDA Related
Photo: Ian Prince / StockSnap (CC0) / own upload
FDA's 1 May proposal not to put three GLP-1-class ingredients on the 503B bulks list closed for comment on 30 June; no final notice found in the Federal Register as of 4 October. Federal Register (FDA notice 2026-08552)
Research Buzz
Photo: frank mckenna / StockSnap (CC0) / own upload
One-step bicyclization of phage-displayed peptide libraries (PReP-Bicyc). Nature Communications
Photo: Sonja Guina / StockSnap (CC0) / own upload
Elongation factor P improves incorporation of cyclic dipeptides into proteins in vitro. American Peptide Society (Hecht Lab, ACS Chemical Biology)
Also Seen
Photo: Vidsplay / StockSnap (CC0) / own upload
Nature Communications: a new phage-compatible chemistry builds bicyclic peptide libraries in one step; screening against PD-1 found sub-micromolar binders. Nature Communications (Jin et al.)
Photo: Vidsplay / StockSnap (CC0) / own upload
American Peptide Society highlights Arizona State work showing elongation factor P boosts ribosomal incorporation of bulky cyclic dipeptides in vitro. American Peptide Society (summary of ACS Chemical Biology paper)
Photo: Krzysztof PuszczyΕski / StockSnap (CC0) / own upload
SK pharmteco plans more than $200M over five years for US small-molecule and peptide capacity, including GMP kilo-scale peptide work slated for late 2026. Pharma Manufacturing (via Megaproject)
Photo: Artem Verbo / StockSnap (CC0) / own upload
A KSL consumer segment quoted a pharmacist citing a study in which 61% of 2,600 online peptide samples didn't match their labels; the segment didn't name the study. KSL.com
Research-community awareness only β not legal advice. For research use only. Not for human or veterinary use. Not a drug, food, or cosmetic.
